Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Eur J Clin Pharmacol ; 79(6): 753-758, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37010536

RESUMEN

PURPOSE: Although hypnotic drug use is a known risk factor for falls, few reports have analyzed fall risk associated with individual hypnotic drugs after adjusting for confounding factors. While it is recommended that benzodiazepine receptor agonists not be prescribed for older adults, it is unknown whether melatonin receptor agonists and orexin receptor antagonists are safe in this population. Here, we aimed to assess the influence of various hypnotic drugs on fall risk in older patients admitted to acute care hospitals. METHODS: We investigated the relationship between nocturnal falls and sleeping pill use in 8,044 hospitalized patients aged > 65 years. We used a propensity score matching method to homogenize characteristics of patients with and without nocturnal falls (n = 145 patients per group) using 24 extracted factors (excluding hypnotic drugs) as covariates. RESULTS: Our analysis of fall risk for each hypnotic drug revealed that benzodiazepine receptor agonists were the only drugs significantly associated with falls, suggesting that use of the drugs is a risk factor for falls in older adults (p = 0.003). In addition, a multivariate analysis of 24 selected factors, excluding hypnotic drugs, revealed that patients with advanced recurrent malignancies were at greatest risk of experiencing falls (OR: 2.62; 95% CI: 1.23-5.60; p = 0.013). CONCLUSION: Benzodiazepine receptor agonists should be avoided in older hospitalized patients since they increase fall risk, with melatonin receptor agonists and orexin receptor antagonists used instead. Particularly, fall risk associated with hypnotic drugs should be considered in patients with advanced recurrent malignancies.


Asunto(s)
Hipnóticos y Sedantes , Neoplasias , Humanos , Anciano , Hipnóticos y Sedantes/efectos adversos , Accidentes por Caídas , Receptores de GABA-A , Antagonistas de los Receptores de Orexina , Receptores de Melatonina , Hospitales
2.
Brain Dev ; 44(3): 259-262, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34782199

RESUMEN

BACKGROUND: Developmental disorders associated with Becker muscular dystrophy (BMD), possibly resulting from a lack of dystrophin in the brain, have been reported, but their importance is not fully understood. We report a case of a BMD patient who had been socially withdrawn due to mental retardation and autism spectrum disorder and could not receive appropriate medical services, resulting in delayed detection of severe cardiomyopathy and embolic strokes which developed as complications of BMD. CASE REPORT: The case is a 41-year-old male. In elementary school, he was the slowest runner in his class and had poor grades. He started missing school due to bullying in junior high school and had been socially withdrawn for 24 years. He developed difficulty walking due to progressive muscle weakness in the extremities and lost ambulation at age 36. At age 41, he was referred to our hospital by public health support services to address his social withdrawal. Muscle biopsy led to the diagnosis of BMD. Psychological examination revealed mild mental retardation and autism spectrum disorder, which may have resulted in social isolation. He had severe cardiomyopathy and asymptomatic cerebral infarction due to heart failure. CONCLUSION: In BMD patients, developmental disorders can potentially hinder access to appropriate medical treatment. BMD is an important differential diagnosis for physically disabled children with developmental disorders. Early intellectual and psychological interventions and evaluation of complications are important for improving patient prognosis and quality of life.


Asunto(s)
Distrofia Muscular de Duchenne/diagnóstico , Trastornos del Neurodesarrollo/diagnóstico , Adulto , Diagnóstico Tardío , Humanos , Masculino
3.
Brain Nerve ; 73(10): 1087-1097, 2021 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-34615746

RESUMEN

Intravascular large B-cell lymphoma is an extranodal large B-cell lymphoma characterized by the selective growth of tumor cells in small vessels. It is often difficult to diagnose because of its various and non-specific manifestations. A key to diagnosis is an understanding of how to suspect this disease and performing tissue diagnoses including random skin biopsy. Due to advances in treatment, the importance of early diagnosis is increasing. However, as the pathogenesis and manifestations of the disease are still unclear, additional knowledge is needed.


Asunto(s)
Linfoma de Células B , Humanos
4.
Rinsho Shinkeigaku ; 61(6): 373-377, 2021 Jun 29.
Artículo en Japonés | MEDLINE | ID: mdl-34011808

RESUMEN

A 64-year-old female developed Parkinson's disease at the age of 52 years. She experienced muscle weakness in the upper right extremities and dropped head at 62 and 63 years, respectively; both symptoms were considered to be associated with Parkinson's disease (PD). The dosage of L-DOPA was increased from 200 mg/day to 900 mg/day; however, her neurological symptoms did not improve. Eventually, she was diagnosed with amyotrophic lateral sclerosis (ALS) at 64 years. She was placed under palliative care, and died of respiratory failure and malnutrition. Neuropathologic findings were consistent with the coexistence of PD and ALS. In fact, there were α-synuclein immunoreactive Lewy bodies (Braak stage 4) as well as TDP-43 immunoreactive deposits in the motor nuclei at the level of brainstem and spinal cord. Therefore, coexisting pathologies must be taken into account in a patient showing multi-system symptoms.


Asunto(s)
Esclerosis Amiotrófica Lateral , Enfermedad de Parkinson , Esclerosis Amiotrófica Lateral/complicaciones , Autopsia , Femenino , Humanos , Persona de Mediana Edad , Debilidad Muscular/etiología , Paresia , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico
6.
Chem Commun (Camb) ; (7): 820-2, 2008 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-18253515

RESUMEN

A novel chiral metal-organic framework, [Cu(2)(5,5'-BDA)(2)] was synthesized by treating chiral 2,2'-dihydroxy-1,1'-binaphthalene-5,5'-dicarboxylic acid (5,5'-H(2)BDA) with a Cu(II) ion, in which the asymmetric ring opening reaction of an epoxide with amine proceeds efficiently under solvent-free conditions.


Asunto(s)
Aminas/química , Cobre/química , Compuestos Epoxi/química , Compuestos Organometálicos/química , Cristalografía por Rayos X , Modelos Moleculares , Conformación Molecular , Compuestos Organometálicos/síntesis química , Porosidad , Difracción de Polvo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA